Sign in
Not yet recruitingNo phase

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B

Key facts

Who runs it
University of Ulm
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
15 people, planned
Starts
1 Jan 2027
Expected to end
30 Jun 2029
Type of study
Observational
Treatments tested
  • Metabolic and epigenetic characterization of mothers and fetuses
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Pregnant women from gestational week 13+0
  • No known underlying medical conditions i
  • No known underlying diseases
  • Understanding and voluntary signing of a consent form before study- related examinations

Who cannot take part

  • Regular use of medication during pregnancy
  • Drug and/or alcohol abuse
  • Type 1 or type 2 diabetes mellitus
  • Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
  • Current depression or other psychiatric disorders
  • Eating disorders
  • Pre-existing cardiovascular disease
  • Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion
  • Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
  • Transaminase elevation of 2 times the upper norm
  • Age < 18 years
  • C-reactive protein > 10 mg/l
  • No consent to be informed about incidentally discovered pathological findings

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.

Read full original descriptionShow less

The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.

The group in the trial

  • Pregnant women

    Metabolic and epigenetic characterization

    Treatment: Metabolic and epigenetic characterization of mothers and fetuses

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
18 November 2026